To analyze whether topical application of corticosteroids inhibits inflammatory corneal lymphangiogenesis and to study the potential underlying antilymphangiogenic mechanisms.
T HE HEALTHY CORNEA IS DEvoid of both blood and lymphatic vessels and actively maintains its avascularity. [1] [2] [3] However, a variety of inflammatory conditions can lead to a breakdown of this "angiogenic privilege." This leads to the outgrowth of blood as well as lymphatic vessels from the limbus into the avascular cornea, reducing transparency and visual acuity. [4] [5] [6] Furthermore, corneal neovascularization is also the most important risk factor for graft rejection after corneal transplantation; in particular, lymphangiogenesis has been shown to be essential in mediating immune reactions after corneal grafting. 4, [7] [8] [9] By use of the murine model of corneal transplantation, it has recently been shown that inhibition of corneal neovascu-larization after low-and high-risk corneal transplantation promotes graft survival. [10] [11] [12] [13] Thus, antiangiogenic therapy is a very reasonable approach for reducing corneal complications secondary to inflammation and also for preventing immune rejections after corneal transplantation.
Recently, several specific angiogenesis inhibitors have been approved by the US Food and Drug Administration for the treatment of pathologic neovascularization in the eye. Ranibizumab (Lucentis; Genentech, South San Francisco, California) and pegaptanib (Macugen; OSI Pharmaceuticals, Farmingdale, New York) were both approved for the treatment of agerelated macular degeneration. Bevacizumab (Avastin; Genentech, South San Francisco, California), approved for co-lorectal cancer and nonsmall cell lung cancer treatment, is also widely used off-label to treat age-related maculopathy, proliferative retinopathies, and neovascular glaucoma. 14 In contrast, no specific angiogenesis inhibitor against neovascularization at the anterior segment of the eye has been approved by the US Food and Drug Administration so far. 15 However, many older, established drugs also have antiangiogenic properties in addition to their known activities. For instance thalidomide, spironolactone, nonsteroidal anti-inflammatory drugs, and corticosteroids are well-known drugs with known toxicity profiles, and it has been shown that these substances can inhibit angiogenesis in various immune and inflammatory diseases, including those of the eye. [16] [17] [18] [19] [20] [21] Corticosteroids are potent anti-inflammatory drugs widely used for the treatment of macular edema and choroidal and retinal neovascularization. 22 To date, corticosteroid therapy is also the standard anti-inflammatory and antiangiogenic treatment for patients with corneal neovascularization, especially after corneal transplantation. 15, 23, 24 Although it has been established that corticosteroids are able to inhibit corneal hemangiogenesis, 15, 21, 23, 25 little is known about their ability to suppress corneal lymphangiogenesis. 26, 27 Nakao and colleagues 21 showed that systemic application of dexamethasone sodium phosphate was able to inhibit interleukin 1␤ (IL-1␤)-induced corneal hemangiogenesis. However, to our knowledge, it has not been shown whether corticosteroids are also able to inhibit corneal lymphangiogenesis. Therefore, the aims of our study were to assess whether topical application of corticosteroids is able to inhibit inflammatory corneal lymphangiogenesis and to compare the antilymphangiogenic potential of various clinically used corticosteroids (fluorometholone, prednisolone acetate, and dexamethasone). Furthermore, we analyzed the effect of steroids on inflammatory cell recruitment and proinflammatory cytokine expression by macrophages, which are known to be crucial mediators of inflammatory corneal lymphangiogenesis. 28 In addition, we investigated whether steroids are also able to directly suppress the proliferation of lymphatic endothelial cells (LECs).
METHODS

ANIMALS AND ANESTHESIA
All animal protocols were approved by the local animal care committee and were in accordance to the Association for Research in Vision and Ophthalmology's Statement for the Use of Animals in Ophthalmology and Vision Research. Mice were anesthetized with an intraperitoneal injection of a combination of 8 mg/kg of ketamine hydrochloride and 0.1 ml/kg of xylazine hydrochloride. All mice were female BALB/c mice, aged 6 to 8 weeks (purchased from Charles River Laboratories, Sulzfeld, Germany).
SUTURE-INDUCED, INFLAMMATORY CORNEAL NEOVASCULARIZATION ASSAY
The mouse model of suture-induced inflammatory corneal neovascularization was used as previously described. 13, 28, 29 Prior to corneal neovascularization, each animal was deeply anesthe-tized. The cornea actively maintains its avascularity; in particular, the corneal epithelium contains antiangiogenic molecules such as soluble vascular endothelial growth factor receptor 1 and membrane bound vascular endothelial growth factor receptor 3. 2,3 Therefore, to obtain higher angiogenic and inflammatory response rates, the central cornea was marked with a 2.0-mm diameter trephine and de-epithelialized before suture placement. Three 11-0 nylon sutures (Serag Wiessner, Naila, Germany) were then placed intrastromally with 2 stromal incursions extending over 120°of corneal circumference each. The outer point of suture placement was chosen near the limbus, and the inner suture point was chosen near the corneal center equidistant from limbus to obtain standardized angiogenic responses. Sutures were left in place for 7 days. Treatment groups were as follows: fluorometholone, prednisolone, and dexamethasone (each at a dosage of 1 mg/mL, 3 eye drops daily, 5 µL per drop). It has previously been shown that when fluorometholone, prednisolone, and dexamethasone are all formulated at a concentration of 0.1%, the intraocular penetration of these steroids is almost identical. 30 Therefore, we decided to use all steroids at a concentration of 0.1%, although prednisolone is clinically used at a concentration of 1%. Control mice received equal amounts of saline solution. After 1 week, mice were killed and corneas were prepared. The corneal neovascularization assay included 12 mice per group.
CORNEAL WHOLE MOUNTS AND MORPHOLOGICAL DETERMINATION OF LYMPHANGIOGENESIS AND HEMANGIOGENESIS
The excised corneas from the corneal neovascularization assay were rinsed in phosphate-buffered saline (PBS) and fixed in acetone for 30 minutes. After 3 washing steps in PBS and blocking with 2% bovine serum albumin in PBS for 2 hours, the corneas were stained overnight at 4°C with rabbit anti-mouse lymphatic vessel endothelial hyaluronan receptor 1 (1:500; AngioBio Co, Del Mar, California) and rat anti-mouse CD31-FITC (1:50; Acris Antibodies GmbH, Hiddenhausen, Germany). On day 2, the tissue was washed 3 times; lymphatic vessel endothelial hyaluronan receptor 1 was then detected with a Cy3-conjugated secondary goat anti-rabbit antibody (1:100; Dianova, Hamburg, Germany). After 3 additional washing steps in PBS, all corneas were moved to Superfrost slides (Menzel-Gläser, Braunschweig, Germany) and covered with Dako fluorescent mounting medium (Hamburg, Germany) and stored at 4°C in the dark.
Stained whole mounts were analyzed with a fluorescence microscope (BX51; Olympus Optical Co, Hamburg, Germany), and digital pictures were taken with a 12-bit monochrome chargecoupled device camera (F-View II; Soft Imaging System, Mü nster, Germany). Each whole-mount picture was assembled out of 9 pictures taken at 100ϫ magnification. The areas covered with lymphatic and blood vessels were detected with an algorithm established in the image-analyzing program cell^F (Soft Imaging System, Mü nster, Germany): prior to analysis, gray-value images of the whole-mount pictures were modified by several filters, and vessels were detected by threshold setting, including the bright vessels and excluding the dark background. A detailed explanation of this method was described previously. 31 The mean vascularized area of the control whole mounts was defined as being 100%, and the vascularized areas were then related to this value. nisolone, dexamethasone (each at a dosage of 1 mg/mL, 3 eye drops daily, 5 µL per drop), or saline solution (control). On days 2 and 5 after suture placement, corneas (3 per group) were harvested and pooled. Single-cell suspensions were prepared from corneal samples using collagenase digestion, as previously described. 32 Briefly, corneal buttons were removed and minced into small fragments, followed by digestion with 2 mg/mL of type IV collagenase (Sigma-Aldrich, St Louis, Missouri) and 0.05 mg/mL of deoxyribonuclease I (Roche, Basel, Switzerland) for 1 hour at 37°C with agitation. The suspension was then triturated through a 10-mL syringe to homogenize the remaining tissue and filtered through a 70-µm cell strainer. Once in single-cell suspension, all samples underwent Fc receptor blockade via incubation with ␣-CD16/CD32 (BD Pharmingen, San Diego, California) at 4°C in 0.5% bovine serum albumin (Sigma-Aldrich). Subsequent antibody labeling included ␣-CD11b (BD Pharmingen) and ␣-F4/80 (BD Pharmingen). All antibodies were analyzed with the appropriate isotype controls.
COLLECTION, CULTURE, AND TREATMENT OF PERITONEAL MACROPHAGES
Thioglycollate-induced macrophages were collected from the peritoneal cavity (peritoneal exudate cells) of 8-week-old female mice as described previously. 33 Peritoneal exudate cells were washed, resuspended, and cultured at 37°C in RPMI-1640 medium containing 10% fetal calf serum, 10mM HEPES, 1mM nonessential amino acids, 1mM sodium pyruvate, 2mM L-glutamine, 100-U/mL penicillin, and 100-mg/mL streptomycin. After adhesion, nonadherent cells were removed by washing with culture medium, and adherent cells were then used as macrophages. Cells collected by this method are F4/80ϩ (Ͼ90%) and CD11bϩ (Ͼ99%). 33, 34 Cells were incubated in RPMI-1640 medium containing 25 nmol/L of fluorometholone, prednisolone, or dexamethasone for 24 hours, followed by RNA isolation. To analyze RNA expression under higher inflammatory conditions, 50 ng/mL of tumor necrosis factor (TNF; Biomol GmbH, Hamburg, Germany) was added in some experiments, and cells were then incubated for 24 hours with or without 25 nmol/L of dexamethasone.
RNA ISOLATION AND REAL-TIME POLYMERASE CHAIN REACTION
RNA from cultured peritoneal macrophages was isolated with the RNeasy Micro kit (Qiagen, Hilden, Germany). Complementary DNA was synthesized with random hexamers using reverse transcriptase (SuperScript III; Invitrogen, Darmstadt, Germany) according to the manufacturer's recommendations. Real-time polymerase chain reaction (PCR) was performed using TaqMan Universal PCR Mastermix and preformulated primers for TNF (assay Mm99999068_m1), IL-1␤ (assay Mm00434228_m1), and GAPDH (assay Mm99999915_g1); FAM-MGB dye-labeled predesigned primers were used for TNF, IL-1␤, and GAPDH (Applied Biosystem, Foster City, California). The results were analyzed by the comparative threshold cycle method and normalized by GAPDH as an internal control.
The relative messenger RNA (mRNA) level in the untreated group was used as the normalized control for the treatment groups. All assays were performed in duplicate; a nontemplate control was included in all of the experiments to evaluate DNA contamination of the reagents used. Experiments were conducted twice.
LEC PROLIFERATION ENZYME-LINKED IMMUNOSORBENT ASSAY
The LEC proliferation enzyme-linked immunosorbent assay (ELISA) was used, with slight modifications, as previously described. 13 Human lymphatic microvascular endothelial cells (Cambrex Bio Science, Walkersville, Maryland) were cultured in EGM2-MV full medium (Cambrex Bio Science) according to the manufacturer's instructions; EGM2-MV full medium contains endothelial cell growth factors such as vascular endothelial growth factor and basic fibroblast growth factor. For this ELISA, cells were seeded in a 96-well plate in EGM2-MV medium at a density of 4ϫ10 3 cells per well. After 6 hours, the medium was replaced with a serum-free medium, 10 µL/mL of 5-bromodeoxyuridine (BrdU; Cell Proliferation ELISA, BrdU, Roche, Penzberg, Germany), and the corticosteroids (25 nmol/L of fluorometholone, prednisolone, or dexamethasone) were added. Cells were fixed and stained after 48 hours according to the manufacturer's instructions. Colorimetric analysis was performed with the ELISA reader SLT Spectra (SLT Labinstruments Deutschland GmbH, Crailsheim, Germany). The mean extinction of the control wells was defined as being 100%, and extinction of all wells were then related to this value (LEC proliferation ratio). ; P Ͻ .001). The inhibitory effect of fluorometholone was again significantly weaker than the inhibitory effect of prednisolone or dexamethasone (P Ͻ.01) (Figure 1 ). ( 
STATISTICAL ANALYSIS
RESULTS
INHIBITORY EFFECT OF TOPICAL TREATMENT WITH CORTICOSTEROIDS ON CORNEAL LYMPHANGIOGENESIS AND HEMANGIOGENESIS IN VIVO
INHIBITORY EFFECT OF TOPICAL TREATMENT WITH CORTICOSTEROIDS ON INFLAMMATORY CELL RECRUITMENT IN VIVO
To examine the effect of topical corticosteroid treatment on suture-induced macrophage infiltration, we quantified the number of F4/80ϩCD11bϩ cells using flow cytometry. Fluorescence-activated cell sorting analysis showed that topical treatment with corticosteroids resulted in a significant reduction of inflammatory cell recruitment in vivo. Although, in control corneas, the percentage of F4/ 80ϩCD11bϩ macrophages per cornea was 23.58% at 2 days after corneal suture placement and 27.14% at 5 days after corneal suture placement, treatment with fluorometholone reduced the amount of F4/80ϩCD11bϩ cells to 2.07% at day 2 and 13.57% at day 5. Treatment with prednisolone reduced the amount of F4/80ϩCD11bϩ cells to 4.51% at day 2 and 10.44% at day 5, and treatment with dexamethasone reduced the amount of F4/80ϩCD11bϩ cells to 1.88% at day 2 and 11.86% at day 5. All of the steroids used led to a stronger inhibitory effect on macrophage recruitment on day 2 than on day 5 (Figure 2 ).
SUPPRESSIVE EFFECT OF CORTICOSTEROIDS ON PROINFLAMMATORY CYTOKINE EXPRESSION BY MACROPHAGES IN VITRO
Peritoneal exudate cells were incubated with 25-nmol/L fluorometholone, prednisolone, or dexamethasone for 24 hours, and mRNA expression levels of the proinflammatory cytokines TNF and IL-1␤ were then measured via real-time PCR. In vitro treatment of resting peritoneal exudate cells with corticosteroids led to a significant inhibition of mRNA expression levels of TNF and IL-1␤. Fluorometholone treatment inhibited mRNA expression levels by 83% (TNF) and 68% (IL-1␤), whereas prednisolone treatment suppressed mRNA expression levels by 79% (TNF) and 50% (IL-1␤). Dexamethasone was the strongest inhibitor of proinflammatory cytokine expression: TNF expression was reduced by 88%, and IL-1␤ expression by 73%. With respect to TNF expression levels, there were no significant differences detectable between fluorometholone treatment and prednisolone treatment (PϾ.05) or between fluorometholone treatment and dexamethasone treatment (PϾ.05). However, treatment with dexamethasone showed a statistically stronger inhibition of TNF mRNA expression than did treatment with prednisolone (P Ͻ.05). The assessment of IL-1␤ mRNA levels revealed that both fluorometholone and dexamethasone had a stronger inhibitory effect on IL-1␤ expression than did prednisolone (P Ͻ.01), with the effect of fluorometholone and dexamethasone being comparable (PϾ .05).
To analyze whether steroids can also inhibit TNF and IL-1␤ expression under higher inflammatory conditions, peritoneal exudate cells were incubated with 50 ng/mL of TNF. The addition of this inflammatory stimulus led to a strong upregulation of proinflammatory cytokine expression (a 4.6-fold increase in TNF expression and a 4.4-fold increase in IL-1␤ expression). However, further treatment with dexamethasone could still suppress proinflammatory cytokine expression, even under this inflammatory stimulation (a 0.3-fold decrease TNF expression and a 0.4-fold decrease IL-1␤ expression) (Figure 3 ).
SUPPRESSIVE EFFECT OF CORTICOSTEROIDS ON LEC PROLIFERATION IN VITRO
To assess whether corticosteroids have a direct effect on LECs as well, we studied their effect on LEC proliferation in vitro. Treatment with corticosteroids (dose, 25 nmol/L) significantly suppressed the proliferation of LECs. Compared with controls, application of fluorometholone resulted in an inhibition of LEC proliferation by 42% (PϽ.001), application of prednisolone resulted in an inhibition of LEC proliferation by 30% (P Ͻ.001), and application of dexamethasone resulted in an inhibition of LEC proliferation by 51% (P Ͻ.001). Between the ana-lyzed steroids, prednisolone had the weakest effect on LEC proliferation (prednisolone vs fluorometholone [P Ͻ .01]; prednisolone vs dexamethasone [P Ͻ .001]). Dexamethasone was the strongest inhibitor of LEC proliferation (dexamethasone vs fluorometholone; PϽ.05) (Figure 4) .
COMMENT
The experiments performed in our study demonstrate the following: (1) Corticosteroids are potent inhibitors of inflammation-induced lymphangiogenesis and hemangiogenesis in vivo. (2) Significant differences exist between different corticosteroids with respect to their antilymphangiogenic and antihemangiogenic properties. In general, the stronger the anti-inflammatory effect, the stronger the in vivo antilymphangiogenic and antihemangiogenic effect. This fits well with the known close interrelation between inflammation and angiogenesis. (3) Corticosteroids strongly block inflammatory cell recruitment into the inflamed cornea. It has already been shown that systemic application of dexamethasone was able to inhibit the recruitment of CD11b single positive cells after IL-1␤ pellet implantation. 21 We analyzed the effect of topical steroid treatment on F4/ 80ϩCD11bϩdouble-positivecellsaftercornealsutureplacement in order to primarily focus on the role of macrophages, because various leukocyte populations (eg, granulocytes and natural killer cells) also express CD11b, whereas F4/ 80 seems to be mainly expressed by macrophages. 35, 36 Furthermore, compared with pellet implantation, the sutureinducedneovascularizationmodelusedinourstudyisknown to induce a strong inflammatory response. The inhibition of F4/80ϩCD11bϩ macrophage infiltration by steroids af- ter suture placement allowed us to conclude that, even under these very high inflammatory conditions, corticosteroids strongly block macrophage recruitment after topical application. (4) In vitro, corticosteroids significantly inhibit proinflammatory cytokine expression by macrophages. It is well established that both TNF and IL-1␤ mediate corneal neovascularization. 37, 38 In particular, TNF expressed by macrophages is known to be an important factor that induces angiogenesis. 39 We could show that steroids are able to suppressproinflammatorycytokineexpression,bothunderrest-ing and inflammatory conditions. Therefore, blockade of macrophage-derived expression of TNF and IL-1␤ levels by steroids likely contributes to the strong antilymphangiogenic effect of these substances. (5) Moreover, corticosteroids also suppress LEC proliferation, indicating that the antilymphangiogenic effect of these substances is due not only to anti-inflammatory properties but also partly to direct anti-proliferative properties. Fluorometholone,theweakestofthe3anti-inflammatory corticosteroids tested, had the least effect on corneal lymphangiogenesis in vivo; however, it did have a stronger inhibitory effect than did prednisolone in vitro. Prednisolone had significantly stronger inhibitory effects in vivo; however, it had the weakest inhibitory effect in vitro. Therefore, additional properties (eg, tissue and cell penetration and substance half-life) also seem to be responsible for the overall inhibitory effect in vivo. Indeed, it has been shown that fluorometholone has a relatively short half-life and rapid metabolism. 40 Dexamethasone was the most potent inhibitor in almost all conducted experiments. The different antilymphangiogenic potentials of these 3 corticosteroids should be taken into account when using them in clinical practice (eg, after keratoplasty). Also, however, the risk of adverse effects seems to decrease in parallel with the anti-inflammatory potency of the particular steroid. For example, it has been established that fluorometholone increases intraocular pressure less frequently than does prednisolone or dexamethasone. The benefit of a steroid with higher antiinflammatory and, as shown in our study, also higher antiangiogenic properties surely has to be weighed against its increasing risk of adverse effects in patients.
A plethora of clinical indications exist for antiangiogenic treatment of the cornea (eg, to stop sightthreatening neovascularization after inflammation or to improve graft survival after corneal transplantation). 4, [41] [42] [43] [44] [45] To date, steroid therapy is the standard anti-inflammatory and antiangiogenic treatment for patients with corneal neovascularization, especially after corneal transplantation. 15 Furthermore, it is widely accepted that topical steroid treatment protects against immunologic graft rejections after corneal transplantation. 23, 24 This protection may largely be attributable to the fact that corticosteroids are very potent anti-inflammatory substances. The fact that these substances are also able to inhibit lymphangiogenesis, as shown in our study, and that lymphangiogenesis has been shown to be an important risk factor regarding graft rejection after corneal transplantation 4,7 may lead one to conclude that both the antiinflammatory effects and the antilymphangiogenic properties of these substances can result in a better outcome for patients after corneal transplantation.
However, the use of steroid therapy in the management of eye diseases remains controversial because of the adverse effects associated with this type of therapy. 23, 46 Alternative therapeutic approaches are necessary; for example, specifically blocking angiogenesis by targeting vascular endothelial growth factor appears to be a very reasonable and promising approach with less adverse effects. 14, 47 In fact, initial successful results were obtained using specific antiangiogenic drugs at the cornea (eg, bevacizumab eye drops and GS-101 antisense oligonucleotide eye drops). 48, 49 Submitted for Publication: June 2, 2010; final revision received July 28, 2010; accepted September 2, 2010. Correspondence: Claus Cursiefen, MD, Department of Ophthalmology, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Nuremberg, Germany (claus.cursiefen@uk-erlangen.de). Financial Disclosure: None reported. Funding/Support: This study was supported by the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (Project A9) and the German Research Foundation Sonderforschungsbereich 643 (Project B10).
